文献速递冠心病

ST段抬高型心肌梗死患者预处理P2Y12受体拮抗剂:瑞典冠状动脉造影和血管成形术注册报告

Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
PubMed 文献 · Eur Heart J · 2019-01-01

基于瑞典冠状动脉造影和血管成形术注册研究2005至2016年数据,纳入44 804例因STEMI行直接PCI的患者,比较预处理与未预处理P2Y12受体拮抗剂的临床结局。倾向评分校正混合效应逻辑回归显示,预处理与30天全因死亡、梗死相关动脉闭塞、支架血栓、院内出血及神经并发症均无显著关联。

要点

  • 预处理P2Y12受体拮抗剂未改善30天生存(OR 1.08,95%CI 0.95-1.24;P=0.313)。
  • 预处理与梗死相关动脉闭塞、支架血栓风险无显著关联。
  • 预处理未增加院内出血或神经并发症风险。

核心结论

  • STEMI患者预处理P2Y12受体拮抗剂与改善临床结局无关。

研究设计与样本

  • 基于瑞典冠状动脉造影和血管成形术注册研究2005至2016年数据,纳入44 804例因STEMI行直接PCI的患者,按是否预处理P2Y12受体拮抗剂分层,采用倾向评分校正混合效应逻辑回归分析。

主要发现

  • 30天全因死亡2488例(5.6%),支架血栓267例(0.6%)。
  • 预处理与30天生存无关(OR 1.08,95%CI 0.95-1.24;P=0.313)。
  • 预处理与梗死相关动脉闭塞无关(OR 0.98,95%CI 0.92-1.05;P=0.608)。
  • 预处理与支架血栓无关(OR 0.99,95%CI 0.69-1.43;P=0.932)。
  • 预处理与院内出血(OR 1.05,95%CI 0.89-1.26;P=0.526)及神经并发症(OR 0.72,95%CI 0.43-1.21;P=0.210)均无显著关联。

临床怎么用

  • 对于STEMI行直接PCI的患者,预处理P2Y12受体拮抗剂未显示临床获益,临床决策需权衡个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pretreatment of patients with ST-elevation myocardial infarction (STEMI) with P2Y12 receptor antagonists is supported by guidelines and is a common practice despite the lack of definite evidence for its benefit. METHODS AND RESULTS: Using data from the Swedish Coronary Angiography and Angioplasty Registry on procedures between 2005 and 2016, we stratified all patients who underwent primary percutaneous coronary intervention due to STEMI in Sweden by whether or not they were pretreated with P2Y12 receptor antagonists. We investigated associations between pretreatment with P2Y12 receptor antagonists and the risk of adverse outcomes using propensity score-adjusted mixed-effects logistic regression, which accounted for clustering of patients within hospitals. The primary endpoint was all-cause death within 30 days. Secondary endpoints were infarct-related artery (IRA) occlusion, 30-day stent thrombosis, in-hospital bleeding, neurological complications, and cardiogenic shock. In total, 44 804 patients were included. They were treated with clopidogrel (N = 26 136, 58.3%), ticagrelor (N = 15 792, 35.3%), or prasugrel (N = 2352, 5.3%); 37 840 (84.5%) were pretreated, and 30 387 (67.8%) had IRA occlusion. At 30 days, there were 2488 (5.6%) deaths and 267 (0.6%) stent thrombosis. Pretreatment was not associated with better survival at 30 days [odds ratio (OR) 1.08, 95% confidence interval (CI) 0.95-1.24; P = 0.313], reduced IRA occlusion (OR 0.98, 95% CI 0.92-1.05; P = 0.608), decreased stent thrombosis (OR 0.99, 95% CI 0.69-1.43; P = 0.932), higher risk of in-hospital bleeding (OR 1.05, 95% CI 0.89-1.26; P = 0.526), or neurological complications (OR 0.72, 95% CI 0.43-1.21; P = 0.210). CONCLUSION: Pretreatment of STEMI patients with P2Y12 receptor antagonists was not associated with improved clinical outcomes.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Redfors B, Dworeck C, Haraldsson I, et al. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J. 2019. PMID: 30851037. doi:10.1093/eurheartj/ehz069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。